Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, DCPH to report 3Q20 loss of $ 1.3 per share from revenue of $ 7.05 million.
For the full year, analysts anticipate top line of $ 24.04 million, while looking forward to loss of $ 5.22 per share bottom line.
Stock Performance
Shares of Deciphera Pharmaceuticals, Inc. traded up $ 3.85 or 6.35 percent on Wednesday, reaching $ 64.51 with volume of 380.00 thousand shares. Deciphera Pharmaceuticals, Inc. has traded high as $ 65.80 and has cracked $ 60.67 on the downward trend
The closing price of $ 64.51, representing a 83.26 % increase from the 52 week low of $ 33.10 and a 14.7 % decrease over the 52 week high of $ 71.11.
The company has a market capital of $ 3.64 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 14th September 2020, maintained by SVB Leerink at Market Perform rating, with $ 58.00 target price.
Conference Call
Deciphera Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.deciphera.com
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The companys lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors.
